Funding for this research was provided by:
National Institutes of Health (K24 HL092902, K23 DK115903)
Received: 28 March 2023
Accepted: 7 July 2023
First Online: 15 July 2023
: This study was approved by the Mass General Brigham institutional review board and is compliant with the Health Insurance Portability and Accountability Act. Written informed consent was obtained from all participants prior to any study procedures.
: Not applicable.
: KKM has received study medication from Pfizer and has had equity in the following companies—Bristol-Myers Squibb, General Electric, Boston Scientific, and Becton Dickinson. KKM’s financial interests were reviewed and are managed by Massachusetts General Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. All other authors report no conflicts of interest.